Cigna Group stock has delivered a 44.4% gain over the past five years, while the recent share price of US$277.51 comes after a period of weaker short term returns. Valuation checks still indicate the shares screen as undervalued on several fronts.

• The 44.4% total return over five years suggests Cigna Group has rewarded patient shareholders, even though the past year has been more muted.
• For a health insurer, the medium term outlook for membership growth and medical cost control can support earnings. However, any sustained pressure on healthcare utilisation or reimbursement may weigh on what investors are willing to pay for the stock.
• Cigna Group is assessed as undervalued in 6 of 6 valuation checks, which points to a broader set of indicators implying the current market price is below what the fundamentals suggest.

The issue now is whether that apparent discount offers enough compensation for the recent softer share price performance and the risks around future profitability.

Does Cigna Group Look Undervalued on Earnings?

The P/E ratio is a useful measure for Cigna Group because earnings remain a main reference point for how investors typically view large health insurers. Cigna Group trades on a P/E of 11.4x, which is well below the broader Healthcare industry average of 25.5x and also under the peer group average of 31.6x. On simple comparisons, the stock is priced at a sizeable discount to both its sector and closer peers.

A more tailored yardstick, which considers Cigna Group’s growth profile, margins, size and risk, points to a fair P/E ratio of about 28.7x. That is more than double the current multiple. This gap indicates the market is applying a cautious earnings multiple to Cigna Group relative to what this framework suggests could be reasonable for the business.

On the P/E multiple alone, Cigna Group stock appears undervalued compared with both peers and its own modelled fair ratio.

The Cigna Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Cigna Group are designed to bridge the gap between the current P/E discount and what that might imply for the company’s future. Each narrative spells out the earnings, growth and margin assumptions that would need to hold for Cigna Group's stock to be worth materially more or less than today’s price, and presents these drivers in a way you can compare with the company’s reported results over time.

You can add your voice to the Simply Wall St community by sharing a Narrative on Cigna Group that sets out your number driven view on where its growth, margins and execution go from here. Publish a clear case, and then watch how it stacks up as new results and updates come through.

Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying!

The Bottom Line

Cigna Group screens as undervalued on earnings, with the current P/E well below both the broader healthcare industry and its tailored fair multiple. For you as an investor, the key question is whether that discount reflects genuine mispricing or a reasonable buffer for execution and healthcare policy risks. The central issue from here is how confidently you think Cigna Group can balance membership growth with medical cost control. If that balance holds, the current valuation gap may look like an opportunity rather than a warning sign.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.